Total Valuation
Spago Nanomedical AB has a market cap or net worth of €7.99M. The enterprise value is €44.74.
Market Cap€7.99M
Enterprise Value€44.74
Share Statistics
Spago Nanomedical AB has 798,380,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding798,380,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Spago Nanomedical AB’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -97.93%.
Return on Equity (ROE)-0.86
Return on Assets (ROA)-0.72
Return on Invested Capital (ROIC)-97.93%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee72.83K
Profits Per Employee-4.43M
Employee Count6
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spago Nanomedical AB is ―. Spago Nanomedical AB’s PEG ratio is 0.05.
PE Ratio―
PS Ratio99.92
PB Ratio1.42
Price to Fair Value1.42
Price to FCF-1.53
Price to Operating Cash Flow-3.49
PEG Ratio0.05
Income Statement
In the last 12 months, Spago Nanomedical AB had revenue of 437.00K and earned -26.55M in profits. Earnings per share was -0.07.
Revenue437.00K
Gross Profit-19.38M
Operating Income-30.86M
Pretax Income-26.55M
Net Income-26.55M
EBITDA-26.39M
Earnings Per Share (EPS)-0.07
Cash Flow
In the last 12 months, operating cash flow was -21.86M and capital expenditures 14.48M, giving a free cash flow of -16.82M billion.
Operating Cash Flow-21.86M
Free Cash Flow-16.82M
Free Cash Flow per Share-0.02
Dividends & Yields
Spago Nanomedical AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change0.00%
50-Day Moving Average0.01
200-Day Moving Average―
Relative Strength Index (RSI)45.18
Average Volume (3m)0.00
Important Dates
Spago Nanomedical AB upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 20, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Spago Nanomedical AB as a current ratio of 6.96, with Debt / Equity ratio of 0.00%
Current Ratio6.96
Quick Ratio6.96
Debt to Market Cap0.00
Net Debt to EBITDA1.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spago Nanomedical AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spago Nanomedical AB EV to EBITDA ratio is -0.53, with an EV/FCF ratio of -0.49.
EV to Sales32.02
EV to EBITDA-0.53
EV to Free Cash Flow-0.49
EV to Operating Cash Flow-0.49
Balance Sheet
Spago Nanomedical AB has €32.51M in cash and marketable securities with €0.00 in debt, giving a net cash position of €32.51M billion.
Cash & Marketable Securities€32.51M
Total Debt€0.00
Net Cash€32.51M
Net Cash Per Share€0.04
Tangible Book Value Per Share€0.08
Margins
Gross margin is -46335.00%, with operating margin of -7062.70%, and net profit margin of -6076.43%.
Gross Margin-46335.00%
Operating Margin-7062.70%
Pretax Margin-6076.43%
Net Profit Margin-6076.43%
EBITDA Margin-6038.22%
EBIT Margin-6076.43%
Analyst Forecast
The average price target for Spago Nanomedical AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-97.24%
EPS Growth Forecast23.21%